Whole genome sequencing investigation of a tuberculosis outbreak in Port-au-Prince, Haiti caused by a strain with a "low-level"rpoB mutation L511P - Insights into a mechanism of resistance escalation

PLoS ONE

Volumn 10, Issue 6, 2015, Pages

  Ocheretina, Oksana ^a,b   Shen, Lishuang ^c   Escuyer, Vincent E ^d   Mabou, Marie Marcelle ^b   Royal Mardi, Gertrude ^b   Collins, Sean E ^a   Pape, Jean W ^a,b   Fitzgerald, Daniel W ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b Department of Adolescent Medicine   (Haïti)

^c Department of Obstetrics Gynecology   (United States)

^d WADSWORTH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAPREOMYCIN; ETHAMBUTOL PLUS ISONIAZID PLUS PYRAZINAMIDE PLUS RIFAMPICIN; KANAMYCIN; STREPTOMYCIN; BACTERIAL PROTEIN; DNA DIRECTED RNA POLYMERASE; ISONIAZID; RIFAMPICIN; RPOB PROTEIN, MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSTATIC AGENT;

ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENE; BACTERIAL STRAIN; BACTERIUM CULTURE; BACTERIUM ISOLATE; BACTERIUM ISOLATION; CODON; CONTROLLED STUDY; DIAGNOSTIC KIT; EPIDEMIC; FEMALE; GENE MUTATION; GENE SEQUENCE; GENOTYPE; GENOTYPING TECHNIQUE; HAITI; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MEDICAL DECISION MAKING; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR DIAGNOSIS; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PHENOTYPE; PRACTICE GUIDELINE; PREDICTION; TUBERCULOSIS; WHOLE GENOME SEQUENCING; ADOLESCENT; BACTERIAL GENOME; DRUG EFFECTS; GENE EXPRESSION; GENETICS; HIV INFECTIONS; INFANT; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MIXED INFECTION; MULTIDRUG RESISTANCE; MUTATION; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY; VIROLOGY;

MYCOBACTERIUM TUBERCULOSIS;

ADOLESCENT; ADULT; ANTITUBERCULAR AGENTS; BACTERIAL PROTEINS; COINFECTION; DISEASE OUTBREAKS; DNA-DIRECTED RNA POLYMERASES; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; GENE EXPRESSION; GENOME, BACTERIAL; GENOTYPE; HAITI; HIV INFECTIONS; HUMANS; INFANT; ISONIAZID; MALE; MICROBIAL SENSITIVITY TESTS; MUTATION; MYCOBACTERIUM TUBERCULOSIS; RIFAMPIN; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY;

EID: 84934968506     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0129207     Document Type: Article

References (49)

1. Gandhi NR, Nunn P, Dheda K, Schaaf HS, Zignol M, van Soolingen D, et al. Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis. Lancet. 2010; 375: 1830-1843. doi: 10.1016/S0140-6736(10)60410-2 PMID: 20488523
2. World Health Organization. Guidelines for surveillance of drug resistance in tuberculosis. Document WHO/TB/94.178. 1994; Available: http://who.int/tb/publications/1994/en/index.html.
3. Traore H, Fissette K, Bastian I, Devleeschouwer M, Portaels F. Detection of rifampicin resistance in Mycobacterium tuberculosis isolates from diverse countries by a commercial line probe assay as an initial indicator of multidrug resistance. Int J Tuberc Lung Dis. 2000; 4(5): 481-484. PMID: 10815743
4. World Health Organization. Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis. Document WHO/HTM/TB/2014. 2014; Available: http://www.who.int/tb/publications/pmdt-companionhandbook/en/
5. National Committee on Clinical Laboratory Standards. Susceptibility testing of Mycobacteria, Nocardiae, and other aerobic Actinomycetes. Approved standard. NCCLS document M24-A. Wayne, Pennsylvania: NCCLS; 2003.
6. Ramaswamy S, Musser JM. Molecular genetic basis of antimicrobial agent resistance in Mycobacterium tuberculosis: 1998 update. Tuber Lung Dis. 1998; 79(1): 3-29. PMID: 10645439
7. Telenti A, Imboden P, Marchesi F, Lowrie D, Cole S, Colston MJ, et al. Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis. Lancet. 1993; 341: 647-650. PMID: 8095569
8. Boehme CC, Nabeta P, Hillemann D, Nicol MP, Shenai S, Krapp F, et al. Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med. 2010; 363(11): 1005-1015. doi: 10.1056/NEJMoa0907847 PMID: 20825313
9. Lawn SD, Brooks SV, Kranzer K, Nicol MP, Whitelaw A, Vogt M, et al. Screening for HIV-associated tuberculosis and rifampicin resistance before antiretroviral therapy using the Xpert MTB/RIF assay: a prospective study. PLoS Med. 2011; 8(7): e1001067. doi: 10.1371/journal.pmed.1001067 PMID: 21818180
10. Traore H, Fissette K, Bastian I, Devleeschouwer M, Portaels F. Detection of rifampicin resistance in Mycobacterium tuberculosis isolates from diverse countries by a commercial line probe assay as an initial indicator of multidrug resistance. Int J Tuberc Lung Dis. 2010; 4(5): 481-484.
11. Van Deun A, Aung KJ, Bola V, Lebeke R, Hossain MA, de Rijk WB, et al. Rifampin drug resistance tests for tuberculosis: challenging the gold standard. J Clin Microbiol. 2013; 51(8): 2633-2640. doi: 10.1128/JCM.00553-13 PMID: 23761144
12. Chen L, Gan X, Li N, Wang J, Li K, Zhang H. rpoB gene mutation profile in rifampicin-resistant Mycobacterium tuberculosis clinical isolates from Guizhou, one of the highest incidence rate regions in China. J Antimicrob Chemother. 2010; 65(6): 1299-1301. doi: 10.1093/jac/dkq102 PMID: 20356906
13. Yip CW1, Leung KL, Wong D, Cheung DT, Chu MY, Tang HS, et al. Denaturing HPLC for high-throughput screening of rifampicin-resistant Mycobacterium tuberculosis isolates. Int J Tuberc Lung Dis. 2006; 10(6): 625-630. PMID: 16776449
14. Ocheretina O, Escuyer VE, Mabou MM, Royal-Mardi G, Collins S, Vilbrun SC, et al. (2014) Correlation between Genotypic and Phenotypic Testing for Resistance to Rifampin in Mycobacterium tuberculosis Clinical Isolates in Haiti: Investigation of Cases with Discrepant Susceptibility Results. PLoS One. 2014; 9(3): e90569. doi: 10.1371/journal.pone.0090569 PMID: 24599230
15. Van Deun A, Barrera L, Bastian I, Fattorini L, Hoffmann H, Kam KM, et al. Mycobacterium tuberculosis strains with highly discordant rifampin susceptibility test results. J Clin Microbiol. 2009; 47(11): 3501-3506. doi: 10.1128/JCM.01209-09 PMID: 19759221
16. Jamieson FB, Guthrie JL, Neemuchwala A, Lastovetska O, Melano RG, Mehaffy C. Profiling of rpoB mutations and MICs for rifampin and rifabutin in Mycobacterium tuberculosis. J Clin Microbiol. 2014; 52 (6): 2157-2162. doi: 10.1128/JCM.00691-14 PMID: 24740074
17. Williamson DA, Roberts SA, Bower JE, Vaughan R, Newton S, Lowe O, et al. Clinical failures associated with rpoB mutations in phenotypically occult multidrug-resistant Mycobacterium tuberculosis. Int J Tuberc Lung Dis. 2011; 16(2): 216-220.
18. Ioerger TR1, Koo S, No EG, Chen X, Larsen MH, Jacobs WR Jr, et al, Genome analysis of multi- and extensively-drug-resistant tuberculosis from KwaZulu-Natal, South Africa. PLoS One. 2009; 4(11): e7778. doi: 10.1371/journal.pone.0007778 PMID: 19890396
19. Billington OJ, McHugh TD, Gillespie SH. Physiological cost of rifampin resistance induced in vitro in Mycobacterium tuberculosis. Antimicrob Agents Chemother. 1999; 43(8): 1866-1869. PMID: 10428904
20. Mariam DH, Mengistu Y, Hoffner SE, Andersson DI. Effect of rpoB mutations conferring rifampin resistance on fitness of Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2004; 48(4): 1289-1294. PMID: 15047531
21. Gagneux S, Long CD, Small PM, Van T, Schoolnik GK, Bohannan BJ. The competitive cost of antibiotic resistance in Mycobacterium tuberculosis. Science. 2006; 312(5782): 1944-1946. PMID: 16809538
22. Bergval I, Kwok B, Schuitema A, Kremer K, van Soolingen D, et al. Pre-existing isoniazid resistance but not the genotype of Mycobacterium tuberculosis drives rifampicin resistance codon preference in vitro. PLoS One. 2012; 7(1): e29108. doi: 10.1371/journal.pone.0029108 PMID: 22235262
23. Blumberg H. M. Burman WJ, Chaisson RE, Daley CL, Etkind SC, Friedman LN, et al. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med. 2003 167(4), 603-662. PMID: 12588714
24. World Health Organization & Stop TB Initiative. Treatment of tuberculosis: guidelines. 4th edn, Document WHO/HTM/TB/2009.420. 2009; Available: http://whqlibdoc.who.int/publications/2010/9789241547833-eng.pdf
25. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis. Document WHO/HTM/TB/2008.402. 2008; Available: http://whqlibdoc.who.int/publications/2008/9789241547581-eng.pdf?ua=1
26. World Health Organization. Treatment of tuberculosis: guidelines for national programmes- 3rd ed. Document WHO/CDS/TB/2003.313. 2003; Available: http://whqlibdoc.who.int/publications/2010/9789241547833-eng.pdf
27. Gardy JL, Johnston JC, Ho Sui SJ, Cook VJ, Shah L, Brodkin E, et al, Whole-genome sequencing and social-network analysis of a tuberculosis outbreak. N Engl J Med. 2011; 364(8): 730-739. doi: 10.1056/NEJMoa1003176 PMID: 21345102
28. van Soolingen D, Hermans PW, de Haas PE, Soll DR, van Embden JD. Occurrence and stability of insertion sequences in Mycobacterium tuberculosis complex strains: evaluation of an insertion sequence-dependent DNA polymorphism as a tool in the epidemiology of tuberculosis. J Clin Microbiol. 1991; 29(11): 2578-2586. PMID: 1685494
29. McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A, et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 2010; 20: 1297-1303. doi: 10.1101/gr.107524.110 PMID: 20644199
30. DePristo M, Banks E, Poplin R, Garimella K, Maguire J, Hartl C, et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nature Genetics. 2011; 43: 491-498. doi: 10.1038/ng.806 PMID: 21478889
31. McLaren W, Pritchard B, Rios D, Chen Y, Flicek P, Cunningham F. Deriving the consequences of genomic variants with the Ensembl API and SNP Effect Predictor. BMC Bioinformatics. 2010; 26(16): 2069-2070. doi: 10.1093/bioinformatics/btq330 PMID: 20562413
32. Ocheretina O, Merveille YM, Mabou MM, Escuyer VE, Dunbar SA, Johnson WD, et al. Use of Luminex MagPlex(R) Magnetic Microspheres for High-Throughput Spoligotyping of M. tuberculosis Isolates in Port-au-Prince, Haiti. J Clin Microbiol. 2013; 51(7): 2232-2237. doi: 10.1128/JCM.00268-13 PMID: 23658258
33. Köser CU, Bryant JM, Becq J, Török ME, Ellington MJ, Marti-Renom MA, et al. Whole-genome sequencing for rapid susceptibility testing of M. tuberculosis. N Engl J Med. 2013; 369(3): 290-292. doi: 10.1056/NEJMc1215305 PMID: 23863072
34. Zhang H, Li D, Zhao L, Fleming J, Lin N, Wang T, et al. Genome sequencing of 161 Mycobacterium tuberculosis isolates from China identifies genes and intergenic regions associated with drug resistance. Nat Genet. 2013; 45(10): 1255-1260. doi: 10.1038/ng.2735 PMID: 23995137
35. Casali N, Nikolayevskyy V, Balabanova Y, Harris SR, Ignatyeva O, Kontsevaya I, et al. Evolution and transmission of drug-resistant tuberculosis in a Russian population. Nat Genet. 2014; 46(3): 279-286. doi: 10.1038/ng.2878 PMID: 24464101
36. Comas I, Borrell S, Roetzer A, Rose G, Malla B, Kato-Maeda M, et al. Whole-genome sequencing of rifampicin-resistant Mycobacterium tuberculosis strains identifies compensatory mutations in RNA polymerase genes. Nat Genet. 2011; 44(1): 106-110. doi: 10.1038/ng.1038 PMID: 22179134
37. van Belkum A, Struelens M, de Visser A, Verbrugh H, Tibayrenc M. Role of genomic typing in taxonomy, evolutionary genetics, and microbial epidemiology. Clin Microbiol Rev. 2001; 14(3): 547-560. PMID: 11432813
38. Andrews JR, Morrow C, Wood R. Modeling the role of public transportation in sustaining tuberculosis transmission in South Africa. Am J Epidemiol. 2013; 177(6): 556-561. doi: 10.1093/aje/kws331 PMID: 23423215
39. Andrews JR, Morrow C, Walensky RP, Wood R. Integrating social contact and environmental data in evaluating tuberculosis transmission in a South African township. J Infect Dis. 2014; 210(4): 597-603. doi: 10.1093/infdis/jiu138 PMID: 24610874
40. van der Spuy GD, Warren RM, van Helden PD. The role of molecular epidemiology in low-income, high-burden countries. Int J Tuberc Lung Dis. 2009; 13(4): 419-420. PMID: 19335944
41. International Organization for Migration, Displacement Tracking Matrix, Haiti. 2013; Available: https://www.iom.int/files/live/sites/iom/files/pbn/docs/DTM-V2-Report-March-31-2013-English-final.pdf
42. Kremer K, Arnold C, Cataldi A, Gutiérrez MC, Haas WH, Panaiotov S, et al. Discriminatory power and reproducibility of novel DNA typing methods for Mycobacterium tuberculosis complex strains. J Clin Microbiol. 2005; 43(11): 5628-5638. PMID: 16272496
43. Kremer K, van Soolingen D, Frothingham R, Haas WH, Hermans PW, Martín C, et al. Comparison of methods based on different molecular epidemiological markers for typing of Mycobacterium tuberculosis complex strains: interlaboratory study of discriminatory power and reproducibility. J Clin Microbiol. 1999; 37(8): 2607-2618. PMID: 10405410
44. Kato-Maeda M, Ho C, Passarelli B, Banaei N, Grinsdale J, Flores L, et al. Use of whole genome sequencing to determine the microevolution of Mycobacterium tuberculosis during an outbreak. PLoS One. 2013; 8(3): e58235. doi: 10.1371/journal.pone.0058235 PMID: 23472164
45. Walker TM, Ip CL, Harrell RH, Evans JT, Kapatai G, Dedicoat MJ, et al, Whole-genome sequencing to delineate Mycobacterium tuberculosis outbreaks: a retrospective observational study. Lancet Infect Dis. 2013; 13(2): 137-146. doi: 10.1016/S1473-3099(12)70277-3 PMID: 23158499
46. Bryant JM, Schürch AC, van Deutekom H, Harris SR, de Beer JL, de Jager V, et al. Inferring patient to patient transmission of Mycobacterium tuberculosis from whole genome sequencing data. BMC Infect Dis. 2013; 13:110. doi: 10.1186/1471-2334-13-110 PMID: 23446317
47. Safi H, Sayers B, Hazbón MH, Alland D. Transfer of embB codon 306 mutations into clinical Mycobacterium tuberculosis strains alters susceptibility to ethambutol, isoniazid, and rifampin. Antimicrob Agents Chemother. 2008; 52(6): 2027-2034. doi: 10.1128/AAC.01486-07 PMID: 18378710
48. Safi H, Lingaraju S, Amin A, Kim S, Jones M, Holmes M, et al. Evolution of high-level ethambutol-resistant tuberculosis through interacting mutations in decaprenylphosphoryl-β-D-arabinose biosynthetic and utilization pathway genes. Nat Genet. 2013; 45(10): 1190-1197. doi: 10.1038/ng.2743 PMID: 23995136
49. Srivastava S, Musuka S, Sherman C, Meek C, Leff R, Gumbo T. Efflux-pump-derived multiple drug resistance to ethambutol monotherapy in Mycobacterium tuberculosis and the pharmacokinetics and pharmacodynamics of ethambutol. J Infect Dis. 2010; 201(8): 1225-31. doi: 10.1086/651377 PMID: 20210628